Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

APRE

APRE News

Newswire

08:40

Aprea Therapeutics Reports Q3 FY25 Financial Results and Clinical Updates

08:36

Aprea Therapeutics reports Q3 clinical progress, cash position.

08:48

Aprea Therapeutics Pursues Precision Oncology with ATRN-119 and APR-1051 Trials

08:34

Aprea Therapeutics reports positive results in Phase 1 ACESOT-1051 trial.

21:53

Aprea Therapeutics Advances ATRN-119 with Phase 2 Dose Decision, Enhancing Cancer Treatment Efficacy

View More

About APRE

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More